The two companies announced on 3 September 2013 that they had entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Brazil, Canada, Europe and certain other markets. The agreement may also be extended to cover development and commercialization of another biosimilar, pending the outcome of clinical data.

Under the terms of the agreement, Baxter will make an upfront payment of US$30 million. Coherus, which was formed in 2010, will develop the biosimilar and Baxter will make payments of up to US$216 million depending on the achievement of development and regulatory events.

Baxter also made an agreement for biosimilars with Momenta back in 2011 for collaboration on up to six biosimilars [1]. Baxter expects this latest agreement with Coherus to support accelerated entry into the biosimilar market for Baxter.

Dr Ludwig Hantson, President of Baxter’s BioScience business, said that ‘this collaboration and Baxter’s ongoing relationship with Momenta expand Baxter’s pipeline, which now includes several biosimilars in the areas of immunology and oncology.’

Related articles

Sandoz to start phase III etanercept trial

Cipla launches first etanercept ‘similar biologic’ in India

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Baxter and Momenta make biosimilars deal [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 6]. Available from: www.gabionline.net/Biosimilars/News/Baxter-and-Momenta-make-biosimilars-deal

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.